Compare
Mustang Bio, Inc. vs Lisata Therapeutics, Inc. vs Impact Biomedical Inc. vs Lipocine Inc.
| Latest fiscal year | Mustang Bio, Inc. MBIO | Lisata Therapeutics, Inc. LSTA | Impact Biomedical Inc. IBO | Lipocine Inc. LPCN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $170.0K | $32.0K | $1.98M |
| Revenue growth (YoY) | n/a | -83.0% | n/a | -82.3% |
| Gross margin | n/a | n/a | n/m (computed) | n/a |
| Operating margin | n/a | n/m | n/m | -524.7% |
| Net margin | n/a | n/m | n/m | -487.1% |
| Net income | -$1.92M | -$16.59M | -$11.84M | -$9.63M |
| EPS (Diluted) | -$0.39 | -$1.91 | -$0.38 | -$1.69 |
| Operating cash flow | -$5.26M | -$15.95M | -$1.89M | -$9.76M |
| Free cash flow | n/a | -$15.98M | n/a | n/a |
| Cash & equivalents | $17.27M | $15.96M | $3.0K | $5.21M |
| Total assets | $17.59M | $17.74M | $17.41M | $17.01M |
| Total liabilities | $8.06M | $3.14M | $1.85M | $2.53M |
| Shareholders' equity | $9.53M | $14.86M | $12.61M | $14.48M |
| Return on year-end equity | -20.2% | -111.7% | -93.9% | -66.5% |
| Shares outstanding | n/a | 8.83M | 104.62M | 6.16M |
Revenue, most recent five fiscal years
| Fiscal year | Mustang Bio, Inc. | Lisata Therapeutics, Inc. | Impact Biomedical Inc. | Lipocine Inc. |
|---|---|---|---|---|
| Latest | n/a | $170.0K Ended 2025-12-31 | $32.0K Ended 2025-12-31 | $1.98M Ended 2025-12-31 |
| 1 year earlier | n/a | $1.00M Ended 2024-12-31 | n/a | $11.20M Ended 2024-12-31 |
| 2 years earlier | n/a | $0 Ended 2023-12-31 | n/a | -$2.85M Ended 2023-12-31 |
| 3 years earlier | n/a | $0 Ended 2022-12-31 | $50.0K Ended 2022-12-31 | $500.0K Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $16.14M Ended 2021-12-31 |